{"id":"conversion-schedule-week-3","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Insomnia"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1835901","moleculeType":"Small molecule","molecularWeight":"298.34"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking the reabsorption of serotonin, SSRIs like this drug allow more serotonin to be available in the synaptic cleft, which can help improve mood and reduce symptoms of depression and anxiety.","oneSentence":"This drug is a selective serotonin reuptake inhibitor (SSRI) that works by increasing the levels of serotonin in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:31:15.369Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Generalized anxiety disorder"}]},"trialDetails":[{"nctId":"NCT07314372","phase":"PHASE2","title":"FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2026-02-01","conditions":"Unresectable Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma (HCC), Liver Cancer Adult","enrollment":86},{"nctId":"NCT06949111","phase":"PHASE2","title":"Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color）","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2025-05-15","conditions":"Colon Cancer","enrollment":128},{"nctId":"NCT07010393","phase":"PHASE4","title":"Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"Fujian Medical University","startDate":"2025-07-01","conditions":"Thyroid Neoplasms","enrollment":335},{"nctId":"NCT06993025","phase":"PHASE2","title":"Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-05-25","conditions":"Biliary Tract Cancer","enrollment":30},{"nctId":"NCT03670953","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2018-11-06","conditions":"Parkinson's Disease (Disorder)","enrollment":630},{"nctId":"NCT04410198","phase":"PHASE3","title":"Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis Participants","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2020-05-26","conditions":"Anemia Associated With End Stage Renal Disease (ESRD)","enrollment":203},{"nctId":"NCT04484857","phase":"PHASE3","title":"Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2020-07-22","conditions":"Anemia Associated With End Stage Renal Disease","enrollment":283},{"nctId":"NCT01932502","phase":"PHASE4","title":"Evaluation of Onfi Conversion Therapy Replacing Clonazepam in Patients With Medically Refractory Epilepsy","status":"UNKNOWN","sponsor":"St. Joseph's Hospital and Medical Center, Phoenix","startDate":"2013-02","conditions":"Refractory Epilepsy","enrollment":21}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["clobazam (Onfi)"],"phase":"marketed","status":"active","brandName":"Conversion schedule - Week 3","genericName":"Conversion schedule - Week 3","companyName":"St. Joseph's Hospital and Medical Center, Phoenix","companyId":"st-joseph-s-hospital-and-medical-center-phoenix","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This drug is a selective serotonin reuptake inhibitor (SSRI) that works by increasing the levels of serotonin in the brain. Used for Major depressive disorder, Generalized anxiety disorder.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}